Results 131 to 140 of about 3,561 (181)

Binding Mode Prediction of Strand Transfer HIV-1 Integrase Inhibitors Using Tn5 Transposase as a Plausible Surrogate Model for HIV-1 Integrase

open access: yes, 2016
The crystal structure of Tn5 transposaseāˆ’DNA complex was used in docking experiments to predict binding modes of HIV-1 integrase strand transfer inhibitors (INSTIs).
Alba Chimirri (76729)   +3 more
core   +1 more source

Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond

open access: yes, 2012
HIV-1 integrase is one of the three viral enzymes essential to HIV replication. Consequently the development of therapeutics targeting this enzyme has been a major focus of antiretroviral research over the past two decades.
Rutledge, P.   +5 more
core   +1 more source

Prevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan

open access: yesScientific Reports
HIV acquisition has been found to be associated with increased risk of cardiometabolic syndrome in the past. In this study, we attempt to delineate the associated factors of metabolic syndrome among persons living with HIV in a single medical center in ...
Chien-An Tu   +13 more
doaj   +1 more source

Therapeutic Opportunities in Infectious Diseases: Highlights from the Society of Medicines Research Symposium, held on March 14th 2013 at the National Heart & Lung Institute, London, UK

open access: yes, 2013
Collingwood, S P   +7 more
core  

Will Integrase Inhibitors be Used as Microbicides?

open access: yesCurrent HIV Research, 2012
Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections including HIV-1. Despite more than two decades of HIV-1 research, there is still no efficacious HIV-1 vaccine, and the scientific community appears ...
CUZZUCOLI CRUCITTI, GIULIANA   +2 more
openaire   +4 more sources

Integrase inhibitors to treat HIV/Aids

Nature Reviews Drug Discovery, 2005
HIV integrase is a rational target for treating HIV infection and preventing AIDS. It took approximately 12 years to develop clinically usable inhibitors of integrase, and Phase I clinical trials of integrase inhibitors have just begun. This review focuses on the molecular basis and rationale for developing integrase inhibitors.
Yves Pommier   +2 more
exaly   +3 more sources

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors [PDF]

open access: yesJournal of Global Antimicrobial Resistance, 2020
Objectives: This study evaluated the emergence of mutations associated with integrase strand transfer inhibitors (INSTI) resistance (INSTI-RMs) and the integrase evolution in human immunodeficiency virus type 1 (HIV-1) infected patients treated with this
Rossana Scutari   +2 more
exaly   +3 more sources

Allosteric Integrase Inhibitors

open access: yes, 2016
In the recent years, integrase (IN) has emerged as an important new target for the development of anti-HIV-1 agents. The enzyme is involved in a key stage of the retroviral replicative cycle, and interacts with a range of cellular co-factors.
Victoria Hann, Peter Dawson, Mark Ashton
openaire   +2 more sources

Analysis of binding parameters of HIV-1 integrase inhibitors: Correlates of drug inhibition and resistance

open access: yesBioorganic and Medicinal Chemistry, 2009
This study undertook an exploratory data analysis of the binding parameters of HIV-1 integrase inhibitors. The study group involved inhibitors in preclinical development from the diketo acid, pyrroloquinoline and naphthyridine carboxamide families and ...
Constantinos D Zeinalipour-Yazdi   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy